Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4- maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn- positive tumor cells

Cancer Immunology Immunotherapy

Volumn 48, Issue 1, 1999, Pages 1-8

  Ragupathi, Govindaswami ^a   Howard, Lisa ^a   Cappello, Sarah ^a   Koganty, R Rao ^b   Qiu, Dongxu ^b   Longenecker, B Michael ^b   Reddish, Mark A ^b   Lloyd, Kenneth O ^a   Livingston, Philip O ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Biomira Inc   (Canada)

Author keywords

Carbohydrate; Conjugation; Immunogen; Immunotherapy; Sialyl Tn; Vaccine

Indexed keywords

CANCER VACCINE; CARBOHYDRATE ANTIGEN; EPITOPE; MUCIN; SIALIC ACID DERIVATIVE;

ADENOCARCINOMA; AMINATION; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL SORTER; CONJUGATION; DRUG CONFORMATION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINE PRODUCTION;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CANCER VACCINES; CARBOHYDRATE SEQUENCE; CROSS-LINKING REAGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOCYANIN; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALEIMIDES; MICE; MOLECULAR SEQUENCE DATA; MUCINS; NEOPLASMS, EXPERIMENTAL; SHEEP; SUBMANDIBULAR GLAND;

EID: 0032892187     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050542     Document Type: Article

References (47)

1. 1. Adluri S, Helling F, Ogata S, Zhang S, Itzkowitz SH, Lloyd KO, Livingston PO (1995) Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol Immunother 41:185
2. 2. Donnelly JJ, Deck RR, Liu MA (1990) Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine. J Immunol 145:3071
3. 3. Erlanger BF (1973) Principles and methods for the preparation of drug protein conjugates for immunological studies. Pharmacological Rev 25:271
4. 4. Eskola J, Peltola H, Takala AK, Kayhty H, Hakulinen M, Karanko V, Kela E, Rekola P, Ronnberg PR, Samuelson JS (1987) Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. N Engl J Med 317:717
5. 5. Fung PYS, Madej M, Koganty RR, Longenecker BM (1990) Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res 50:4308
6. 6. Guadagni F, Roselli M, Amato T, Cosimelli M, Mannella E, Perri P, Abbolito MR, Cavaliere R, Colcher D, Greiner JW (1991) Tumor-associated glycoprotein-72 serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma. A longitudinal study. Cancer 68:2443
7. 7. Hakomori S (1984) Tumor-associated carbohydrate antigens. Annu Rev Immunol 2:103
8. 8. Helling F, Shang A, Calves M, Zhang S, Ren S, Yu RK, Oettgen HF, Livingston PO (1994) GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res 54:197
9. 9. Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Yao TJ, Oettgen HF, Livingston PO (1995) GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55:2783
10. 10. Itzkowitz SH, Yuan M, Montgomery CK, Kjeldsen T, Takahashi HK, Bigbee WL, Kim YS (1989) Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res 49:197
11. 11. Itzkowitz SH, Bloom EJ, Kokal WA, Modin G, Hakomori S, Kim YS (1990) Sialosyl-Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 66:1960
12. 12. Jennings HJ, Ashton FE, Gamian A, Michon F, Roy R (1987) A chemical modified Group B meningococcal polysaccharide vaccine. In: Bell R, Torrigiani G (eds) Towards better carbohydrate vaccines. Wiley, London, pp 11
13. 13. Kensil CR, Patel U, Lennick M, Marciani D (1991) Separation and characterization of saponins with adjuvant activity from Quillaja saponaria molina cortex. J Immunol 146:431
14. 14. Klaus GG, Cross AM (1974) The influence of epitope density on the immunological properties of hapten-protein conjugates. I. Characteristics of the immune response to hapten-coupled albumen with varying epitope density. Cell Immunol 14:226
15. y oligosaccharide with proteins in mice: towards the design of anticancer vaccines. Cancer Immunol Immunother 45:281
16. 16. Kurosaka A, Kitagawa H, Fukui S, Numata Y, Nakada H, Funakoshi I, Kawasaki T, Ogawa T, Iijima H, Yamashina I (1988) A monoclonal antibody that recognizes a cluster of a disaccharide, Neua2-6GalNAc, in mucin-type glycoproteins. J Biol Chem 263:8724
17. 17. Landsteiner K (1936) Specificity of serological reactions. Springfield, Ill, p 1
18. 18. Livingston PO (1995) Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 145:147
19. 19. Livingston PO (1995) Augmenting the immunogenicity of carbohydrate tumor antigens. Semin Cancer Biol 6:357
20. 20. Livingston PO, Ragupathi G (1997) Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol Immunother 45:10
21. 21. Livingston PO, Adluri S, Helling F, Yao T-J, Kensil CR, Newman MJ, Marciani D (1994) Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 12:1275
22. 22. Livingston PO, Zhang S, Lloyd KO (1997) Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale. Cancer Immunol Immunother 45:1
23. 23. Lloyd KO, Burchell J, Kudryashov V, Yin BWT, Taylor-Papadimitriou J (1996) Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. J Biol Chem 271:33325
24. 24. Longenecker BM, Reddish M, Koganty R, MacLean GD (1993) Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant. Ann New York Acad Sci 690:276
25. 25. MacLean GD, Reddish M, Koganty RR, Wong T, Gandhi S, Smolenski M, Samuel J, Nabholtz JM, Longenecker BM (1993) Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 36:215
26. 26. MacLean GD, Reddish MA, Bowen-Yacyshyn MB, Poppema S, Longenecker BM (1994) Active specific immunotherapy against adenocarcinomas. Cancer Invest 12:46
27. 27. MacLean GD, Miles DW, Rubens RD, Reddish MA, Longenecker BM (1996) Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother 19:309
28. 28. MacLean GD, Reddish MA, Koganty RR, Longenecker BM (1996) Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother 19:59
29. 29. Meredith RF, Khazaeli MB, Plott WE, Saleh MN, Liu T, Allen LF, Russell CD, Orr RA, Colcher D, Schlom J (1992) Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med 33:23
30. 30. Miles DW, Towlson KE, Graham R, Reddish M, Longenecker BM, Taylor-Papadimitriou J, Rubens RD (1996) A randomized phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer 74:1292
31. 31. Nakada H, Inoue M, Numata Y, Tanaka N, Funakoshi I, Fukui S, Mellors A, Yamashina I (1993) Epitopic structure of Tn glycophorin A for an anti-Tn antibody (MLS 128). Proc Natl Acad Sci USA 90:2495
32. 32. O'Boyle KP, Markowitz AL, Khorshidi M, Lalezari P, Longenecker BM, Lloyd KO, Welt S, Wright KE (1996) Specificity analysis of murine monoclonal antibodies reactive with Tn, sialylated Tn, T, and monosialylated (2 → 6) T antigens. Hybridoma 15:401
33. 33. Ogata S, Chen A, Itzkowitz SH (1994) Use of model cell lines to study the biosynthesis and biological role of cancer-associated sialosyl-Tn antigen. Cancer Res 54:4036
34. 34. Osinaga E, Pancino G, Porchet N, Berois N, De Cremoux P, Mistro D, Aubert JP, Calvo F, Roseto A (1994) Analysis of a heterogeneous group of human breast carcinoma associated glycoproteins bearing the Tn determinant. Breast Cancer Res & Treat 32:139
35. 35. Ragupathi G (1996) Carbohydrate antigens as targets for active specific immunotherapy. Cancer Immunol Immunother 43:152
36. 36. Ragupathi G, Meyers M, Adluri S, Ritter G, Livingston PO (1997) Phase I trial with GD3-lactone-KLH conjugate and immunological adjuvant QS-21 vaccine with malignant melanoma. Proc Am Assoc Cancer Res 38:398
37. 37. Ragupathi G, Park TK, Zhang S, Kim IJ, Graber L, Adluri S, Lloyd KO, Danishefsky SJ, Livingston PO (1997) Immunization of mice with conjugates of fully synthetic hexasaccharide globo-H results in antibodies against human cancer cells: a combined chemical-immunological approach to the fashioning of an anticancer vaccine. Angew Chem Int Ed Engl 36:125
38. 38. Ragupathi G, Koganty RR, Qiu DX, Lloyd KO, Livingston PO (1998) A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm. Glycoconjugate J 15:217
39. 39. Schlom J, Siler K, Milenic DE, Eggensperger D, Colcher D, Miller LS, Houchens D, Cheng R, Kaplan D, Goeckeler W (1991) Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate. Cancer Res 51:2889
40. 40. Schlom J, Eggensperger D, Colcher D, Molinolo A, Houchens D, Miller LS, Hinkle G, Siler K (1992) Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 52:1067
41. 41. Schneerrson R, Robbinson JB, Szu SC, Yang Y (1987) Vaccines composed of polysaccharide-protein conjugates: current status, unanswered questions, and prospects for the future. In: Bell R, Torrigiani G (eds) Towards better carbohydrate vaccines. Wiley. London, p 307
42. 42. Svennerholm L (1963) Chromatographic separation of human brain gangliosides. J Neurochem 10:613
43. 43. Werther JL, Rivera-MacMurray S, Bruckner H, Tatematsu M, Itzkowitz SH (1994) Mucin-associated sialosyl-Tn antigen expression in gastric cancer correlates with an adverse outcome. Br J Cancer 69:613
44. 44. Williams DG (1986) Conjugation procedures in enzyme immunoassays. In: Pal SB (ed) Immunoassay technology. Walter de Gruyter, Berlin, p 1
45. 45. Zhang S, Helling F, Lloyd KO, Livingston PO (1995) Increased tumor cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides. Cancer Immunol Immunother 40:88
46. 46. Zhang S, Walberg LA, Ogata S, Itzkowitz SH, Koganty RR, Reddish M, Gandhi SS, Longenecker BM, Lloyd KO, Livingston PO (1995) Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Cancer Res 55:3364
47. 47. Zhang S, Zhang SH, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO, Livingston PO (1997) Selection of tumor antigens as targets for immune attack using immunohistochemistry. II. blood group-related antigens. Int J Cancer 73:50